Molecular Detection of Circulating Cancer Cells in Breast, Ovarian, Colon and Pancreatic Cancer
- To assess frequency of circulating tumor cells (CTCs) in patients with metastatic
ovarian, breast, pancreatic, and colon cancers.
- To assess the variability in number of CTCs between patients with the same tumor type.
- To correlate the number of CTCs with extent of tumor burden as measured by tumor
markers, imaging, and the number of metastatic sites and proliferation and apoptotic
OUTLINE: Blood samples are collected before treatment and analyzed using molecular detection
techniques to detect circulating cancer cells. Samples are assessed by immunofluorescence
for markers of proliferation and survival (e.g., EGFR, phosphorylated EGFR, AKT,
phosphorylated AKT, cytokeratins, MAPK, Src, and FAK).
Observational Model: Cohort, Time Perspective: Prospective
Frequency of circulating cancer cells (CTC)
Charles Erlichman, MD
United States: Federal Government
|Mayo Clinic||Rochester, Minnesota 55905|